Has Sriram Naidu received payments from drug or device companies?

Yes. Drug and device makers reported $3,156 in general payments to Sriram Naidu across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sriram Naidu did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sriram Naidu come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sriram Naidu

Cardiovascular Disease · Garden City, NYNPI 1184601643

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,646 and has fallen 94.7% since, to $141 in 2022.

$3,156in general payments, 2019–2025

Across 118 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amarin Pharma, Inc.$402
Novartis$302
Akcea Therapeutics, Inc.$277
AstraZeneca$260
Amgen$240
Boehringer Ingelheim$228
plus $1K from 12 others

What the payments were for

Food & beverage$3,149100%
Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amarin Pharma, Inc.	11	$402
Novartis	15	$302
Akcea Therapeutics, Inc.	4	$277
AstraZeneca	15	$260
Amgen	7	$240
Boehringer Ingelheim	9	$228
AbbVie	6	$209
Arbor Pharmaceuticals, Inc.	18	$203
Johnson & Johnson	11	$200
E.r. Squibb & Sons, L.L.C.	4	$163
Pfizer	3	$158
Aerie Pharmaceuticals, Inc.	7	$154
Mallinckrodt Enterprises LLC	1	$125
Biotronik Inc.	1	$124
Bausch & Lomb, A Division Of Bausch Health US, LLC	2	$37
Merck	2	$36
Irhythm Technologies, Inc.	1	$22
Gilead	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEGSEDI$246
ZENPEP$148
ACTHAR$125
Repatha$125
ELIQUIS$119
CAMZYOS$118
Vascepa$110

How this compares

$3,156 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Other cardiovascular disease in Garden City

Roger HajjarNew York$5.2M
Szilard VorosStony Brook$3.7M
Gregg StoneNew York$2M
Augustin DelagoAlbany$1.8M
Philippe GenereuxNew York$1.3M
Adam RosenbluthNew York$1.1M
Luigi di BiaseBronx$978K
Vijay IyerAmherst$855K
Megha PrasadNew York$813K
Ronald DagostinoLake Success$782K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →